
NeuroBo Pharmaceuticals NRBO
Annual report 2025
added 03-26-2026
NeuroBo Pharmaceuticals Depreciation & Amortization 2011-2026 | NRBO
Annual Depreciation & Amortization NeuroBo Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 19 K | 20 K | 6 K | 20 K | 48 K | 46 K | 17 K | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 48 K | 6 K | 25.1 K |
Quarterly Depreciation & Amortization NeuroBo Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5 K | 5 K | 4 K | - | 5 K | 6 K | 4 K | - | 1 K | - | 1 K | - | 19 K | 17 K | 12 K | - | 36 K | 24 K | 12 K | - | 12 K | 12 K | 11 K | - | 5 K | 1 K | 1 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 36 K | 1 K | 9.65 K |
Depreciation & Amortization of other stocks in the Biotechnology industry
| Issuer | Depreciation & Amortization | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Amphastar Pharmaceuticals
AMPH
|
31.6 M | $ 21.65 | 1.12 % | $ 1.01 B | ||
|
I-Mab
IMAB
|
23.9 M | - | - | $ 866 M | ||
|
Aeglea BioTherapeutics
AGLE
|
744 K | - | - | $ 1.01 B | ||
|
Aptorum Group Limited
APM
|
1.13 M | $ 0.9 | -0.18 % | $ 6.62 M | ||
|
ACADIA Pharmaceuticals
ACAD
|
920 K | $ 22.3 | 1.55 % | $ 3.7 B | ||
|
Advaxis
ADXS
|
369 K | - | -9.65 % | $ 45.9 M | ||
|
Galectin Therapeutics
GALT
|
1 K | $ 2.37 | 1.72 % | $ 151 M | ||
|
AIkido Pharma
AIKI
|
105 K | - | 1.93 % | $ 17.4 M | ||
|
Heron Therapeutics
HRTX
|
2.31 M | - | - | $ 198 M | ||
|
ImmuCell Corporation
ICCC
|
2.78 M | $ 8.25 | -1.26 % | $ 74.5 M | ||
|
Akouos
AKUS
|
2.49 M | - | 0.23 % | $ 488 M | ||
|
Allakos
ALLK
|
6.14 M | - | - | $ 28.6 M | ||
|
AlloVir
ALVR
|
13 K | - | 4.14 % | $ 49.1 M | ||
|
Ampio Pharmaceuticals
AMPE
|
122 K | - | -11.43 % | $ 502 K | ||
|
Applied Molecular Transport
AMTI
|
3.13 M | - | - | $ 10.1 M | ||
|
Jaguar Health
JAGX
|
1.91 M | $ 0.28 | -27.77 % | $ 653 K | ||
|
Aeterna Zentaris
AEZS
|
58 K | - | 5.93 % | $ 314 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
199 K | - | -2.5 % | $ 5.88 M | ||
|
Aptinyx
APTX
|
122 K | - | -39.0 % | $ 4.57 M | ||
|
AgeX Therapeutics
AGE
|
100 K | - | -10.17 % | $ 12.2 K | ||
|
Aravive
ARAV
|
886 K | - | -13.39 % | $ 1.45 M | ||
|
KalVista Pharmaceuticals
KALV
|
969 K | $ 19.16 | -2.39 % | $ 1.03 B | ||
|
Aridis Pharmaceuticals
ARDS
|
487 K | - | 17.91 % | $ 11.1 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
1.51 M | - | - | $ 26.5 M | ||
|
Aquestive Therapeutics
AQST
|
548 K | $ 4.1 | 0.49 % | $ 438 M | ||
|
Arcutis Biotherapeutics
ARQT
|
700 K | $ 23.42 | 0.69 % | $ 2.98 B | ||
|
Ayala Pharmaceuticals
AYLA
|
162 K | - | - | $ 7.46 M | ||
|
Autolus Therapeutics plc
AUTL
|
8.3 M | $ 1.42 | -1.39 % | $ 378 M | ||
|
Aptose Biosciences
APTO
|
22 K | - | -45.71 % | $ 1.2 M | ||
|
Ligand Pharmaceuticals Incorporated
LGND
|
35.2 M | $ 241.79 | 4.55 % | $ 4.42 B | ||
|
Eli Lilly and Company
LLY
|
2 B | - | - | $ 783 B | ||
|
AVROBIO
AVRO
|
617 K | - | 1083.1 % | $ 745 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
24 K | $ 2.92 | 0.34 % | $ 4.81 M | ||
|
Esperion Therapeutics
ESPR
|
105 K | - | - | $ 399 M | ||
|
BioDelivery Sciences International
BDSI
|
140 K | - | -4.8 % | $ 255 M | ||
|
BeiGene, Ltd.
BGNE
|
142 M | - | 0.49 % | $ 251 B |